Non-motor symptoms in patients with amyotrophic lateral sclerosis: current state and future directions

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive degeneration of both upper and lower motor neurons.

A defining histopathological feature in approximately 97% of all ALS cases is the accumulation of phosphorylated trans-activation response (TAR) DNA-binding protein 43 protein (pTDP-43) aggregates in the cytoplasm of neurons and glial cells within the central nervous system.

Traditionally, it was believed that the accumulation of TDP-43 aggregates and subsequent neurodegeneration primarily occurs in motor neurons.

However, contemporary evidence suggests that as the disease progresses, other systems and brain regions are also affected.

Despite this, there has been a limited number of clinical studies assessing the non-motor symptoms in ALS patients.

These studies often employ various outcome measures, resulting in a wide range of reported frequencies of non-motor symptoms in ALS patients.

The importance of assessing the non-motor symptoms reflects in a fact that they have a significant impact on patients’ quality of life, yet they frequently go underdiagnosed and unreported during clinical evaluations.

This review aims to provide an up-to-date overview of the current knowledge concerning non-motor symptoms in ALS.

Furthermore, we address their diagnosis and treatment in everyday clinical practice.